Congenital adrenal hyperplasia (CAH) is a family of autosomal recessive disorders caused by mutations in genes encoding the enzymes involved in one of the 5 steps of adrenal steroid synthesis or the electron donor P450 oxidoreductase (POR) enzyme. Steroid 21-hydroxylase deficiency (21-OHD), the principal focus of this review, accounts for about 90–95% of all CAH cases, and its biochemical and clinical severity depends on the underlying CYP21A2 gene disruption. Molecular genetic advancements have been achieved in recent years, and the aim of this review is to attempt to highlight its contribution to the comprehension and management of the disease. When possible, we will try to achieve this goal also by providing some results from our personal experience regarding: some aspects of CYP21A2 gene analysis, with basic genotype/phenotype relationships; its crucial role in both genetic counselling and in prenatal diagnosis and treatment in families at risk for 21-OHD; its help in the comprehension of the severity of the disease in patients diagnosed by neonatal screening and possibly treated before an evident salt-loss crisis or before performing adequate blood sampling; its usefulness in the definition of post ACTH 17-hydroxyprogesterone values, discriminating between non-classic, heterozygote and normal subjects; and finally the contribution of genes other than CYP21A2 whose function or dysfunction could influence 21-hydroxylase activity and modify the presentation or management of the disease.

Keywords:
CYP21A2, Genetics, 21-hydroxylase deficiency, Management, Modifier gene, Neonatal screening, POR deficiency, Prenatal diagnosis
1.
Alesci S, Ramsey WJ, Bornstein SR, Chrousos GP, Hornsby PJ, et al: Adenoviral vectors can impair adrenocortical steroidogenesis: clinical implications for natural infections and gene therapy. Proc Natl Acad Sci USA 99:7484–7489 (2002).
2.
Avent ND, Chitty LS: Non invasive diagnosis of fetal sex; utilisation of free fetal DNA in maternal plasma and ultrasound. Prenat Diagn 26:598–603 (2006).
3.
Bachega TA, Billerbeck AE, Marcondes JA, Madureira G, Arnhold IJ, et al: Influence of different genotypes on 17-hydroxyprogesterone levels in patients with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 52:601–607 (2000).
4.
Balsamo A, Cacciari E, Piazzi S, Cassio A, Bozza D, et al: Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980–1995. Pediatrics 98:362–367 (1996).
5.
Balsamo A, Cacciari E, Baldazzi L, Tartaglia L, Cassio A, et al: CYP21 analysis and phenotype/genotype relationship in the screened population of the Italian Emilia-Romagna region.Clin Endocrinol (Oxf) 53:117–125 (2000).
6.
Balsamo A, Cicognani A, Baldazzi L, Barbaro M, Baronio F, et al: CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency. J Clin Endocrinol Metab 88:5680–5688 (2003).
7.
Barbaro M, Lajic S, Baldazzi L, Balsamo A, Pirazzoli P, et al: Functional analysis of two recurrent amino acid substitutions in the CYP21 gene from Italian patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 89:2402–2407 (2004).
8.
Barbaro M, Baldazzi L, Balsamo A, Lajic S, Robins T, et al: Functional studies of two new and two rare mutations in the 21-hydroxylase gene. J Mol Med 84:521–528 (2006).
9.
Bartha JL, Finning K, Soothill PW: Fetal sex determination from maternal blood at 6 weeks of gestation when at risk for 21-hydroxylase deficiency. Obstet Gynecol 101:1135–1136 (2003).
10.
Baumgartner-Parzer SM, Fischer G, Vierhapper H: Predisposition for de novo gene aberrations in the offspring of mothers with a duplicated CYP21A2 gene. J Clin Endocrinol Metab 92:1164–1167 (2007).
11.
Bidet M, Bellanné-Chantelot C, Galand-Portier MB, Tardy V, Billaud L, et al: Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab 94:1570–1578 (2009).
12.
Blanchong CA, Zhou B, Rupert KL, Chung EK, Jones KN, et al: Deficiencies of human complement component C4A and C4B and heterozygosity in length variants of RP-C4-CYP21-TNX (RCCX) modules in Caucasians. The load of RCCX genetic diversity on major histocompatibility complex-associated disease. J Exp Med 191:2183–2196 (2000).
13.
Boon EM, Schlecht HB, Martin P, Daniels G, Vossen RH, et al: Y chromosome detection by real time PCR and pyrophosphorolysis-activated polymerisation using free fetal DNA isolated from maternal plasma. Prenat Diagn 27:932–937 (2007).
14.
Charmandari E, Eisenhofer G, Mehlinger SL, Carlson A, Wesley R, et al: Adrenomedullary function may predict phenotype and genotype in classic 21-hydroxylase deficiency. J Clin Endocrinol Metab 87:3031–3037 (2002).
15.
Chiu RW, Lau TK, Cheung PT, Gong ZQ, Leung TN, et al: Noninvasive prenatal exclusion of congenital adrenal hyperplasia by maternal plasma analysis: a feasibility study. Clin Chem 48:778–780 (2002).
16.
Cirigliano V, Voglino G, Ordoñez E, Marongiu A, Paz Cañadas M, et al: Rapid prenatal diagnosis of common chromosome aneuploidies by QF-PCR, results of 9 years of clinical experience. Prenat Diagn 29:40–49 (2009).
17.
Cooper DY, Levin S, Narasimhulu S, Rosenthal O: Photochemical action spectrum of the terminal oxydase of mixed function oxydase systems. Science 147:400–402 (1965).
18.
David M, Forest MG: Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. J Pediatr 105:799–803 (1984).
19.
Day DJ, Speiser PW, Shultz E, Bettendorf M, Fitness J, et al: Identification of non-amplifying CYP21 genes when using PCR based diagnosis of 21-hydoxylase deficiency in congenital adrenal hyperplasia (CAH) affected pedigrees. Hum Mol Genet 5:2039–2048 (1996).
20.
De Crecchio L: Sopra un caso di apparenze virili in una donna. Morgagni 7:154–188 (1865).
21.
Demirci C, Witchel SF: Congenital adrenal hyperplasia. Dermatol Ther 21:340–353 (2008).
22.
Dubey S, Idicula-Thomas S, Anwaruddin M, Saravanan C, Varma RR, et al: A novel 9-bp insertion detected in steroid 21-hydroxylase gene (CYP21A2): prediction of its structural and functional implications by computational methods. J Biomed Sci 16:3 (2009).
23.
Ezquieta B, Cueva E, Varela J, Oliver A, Fernández J, et al: Non-classical 21-hydroxylase deficiency in children: association of adrenocorticotropic hormone-stimulated 17-hydroxyprogesterone with the risk of compound heterozygosity with severe mutations. Acta Paediatr 91:892–898 (2002).
24.
Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, et al: Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 36:228–230 (2004).
25.
Forest MG, Tardy V, Nicolino M, David M, Morel Y: 21-hydroxylase deficiency: an exemplary model of the contribution of molecular biology in the understanding and management of the disease. Ann Endocrinol 66:225–232 (2005).
26.
Gomes LG, Huang N, Agrawal V, Mendonça BB, Bachega TA, et al: The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency. J Clin Endocrinol Metab 93:2913–2916 (2008).
27.
Gomes LG, Huang N, Agrawal V, Mendonça BB, Bachega TA, et al: Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency. J Clin Endocrinol Metab 94:89–95 (2009).
28.
Gourmelen M, Gueux B, Pham Huu Trung MT, Fiet J, Raux-Demay MC, et al: Detection of heterozygous carriers for 21-hydroxylase deficiency by plasma 21-deoxycortisol measurement. Acta Endocrinol (Copenh) 116:507–512 (1987).
29.
Hughes IA: Disorders of sex development: a new definition and classification. Best Pract Res Clin Endocrinol Metab 22:119–134 (2008).
30.
Hurwitz A, Brautbar C, Milwidsky A, Vecsei P, Milewicz A, et al: Combined 21- and 11 beta-hydroxylase deficiency in familial congenital adrenal hyperplasia. J Clin Endocrinol Metab 60:631–638 (1985).
31.
Huynh T, McGown I, Cowley D, Nyunt O, Leong GM, et al: The clinical and biochemical spectrum of congenital adrenal hyperplasia secondary to 21-hydroxylase deficiency. Clin Biochem Rev 30:75–86 (2009).
32.
Janzen N, Peter M, Sander S, Steuerwald U, Terhardt M, et al: Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 92:2581–2589 (2007).
33.
Kösel S, Burggraf S, Fingerhut R, Dörr HG, Roscher AA, et al: Rapid second-tier molecular genetic analysis for congenital adrenal hyperplasia attributable to steroid 21-hydroxylase deficiency. Clin Chem 51:298–304 (2005).
34.
Koppens PF, Hoogenboezem T, Degenhart HJ: Duplication of the CYP21A2 gene complicates mutation analysis of steroid 21-hydroxylase deficiency: characteristics of three unusual haplotypes. Hum Genet 111:405–410 (2002).
35.
Krone N, Arlt W: Genetics of congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 23:181–192 (2009).
36.
Krone N, Braun A, Rosher AA, Knorr D, Schwarz HP: Predicting phenotype in steroid 21- hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. J Clin Endocrinol Metab 85:1059–1065 (2000).
37.
Krone N, Braun A, Weinert S, Peter M, Roscher AA, et al: Multiplex minisequencing of the 21-hydroxylase gene as a rapid strategy to confirm congenital adrenal hyperplasia. Clin Chem 48:818–825 (2002).
38.
Lajic S, Levo A, Nikoshkov A, Lundberg Y, Partanen J, Wedell A: A cluster of missense mutations at Arg356 of human steroid 21- hydroxylase may impair redox partner interaction. Hum Genet 99:704–709 (1997).
39.
L’Allemand D, Tardy V, Grüters A, Schnabel D, Krude H, et al: How a patient homozygous for a 30-kb deletion of the C4-CYP 21 genomic region can have a nonclassic form of 21-hydroxylase deficiency. J Clin Endocrinol Metab 85:4562–4567 (2000).
40.
Lapaire O, Lu XY, Johnson KL, Jarrah Z, Stroh H, et al: Array-CGH analysis of cell-free fetal DNA in 10 mL of amniotic fluid supernatant. Prenat Diagn 27:616–621 (2007).
41.
Lee HH: The chimeric CYP21P/CYP21 gene and 21-hydroxylase deficiency. J Hum Genet 49:65–72 (2004).
42.
Lee HH, Lee YJ, Chao MC: Comparing the Southern blot method and polymerase chain reaction product analysis for chimeric RCCX detection in CYP21A2 deficiency. Anal Biochem 399:293–298 (2010).
43.
Levine LS, Zachmann M, New MI, Prader A, Pollack MS, et al: Genetic mapping of the 21-hydroxylase-deficiency gene within the HLA linkage group. N Engl J Med 299:911–915 (1978).
44.
Li Y, Zimmerman B, Rusterholtz C, Kang A, Holzgreve W, et al: Size separation of circulatory DNA in maternal plasma permits ready detection of fetal DNA polymorphisms. Clin Chem 50:1002–1011 (2004).
45.
Maron JL, Bianchi DW: Prenatal diagnosis using cell-free nucleic acids in maternal body fluids: a decade of progress. Am J Med Genet C Semin Med Genet 145C:5–17 (2007).
46.
Martin Ritzén E, Lajic S, Wedell A: How can molecular biology contribute to the management of congenital adrenal hyperplasia? Horm Res 53 Suppl 1:34–37 (2000).
47.
Merke DP, Chrousos GP, Eisenhofer G, Weise M, Keil MF, et al: Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med 343:1362–1368 (2000).
48.
Miller WL: Molecular biology of steroid hormone synthesis. Endocr rev 9:295–318 (1988).
49.
Miller WL: P450 oxidoreductase deficiency. A new disorder of steroidogenesis with multiple clinical manifestations. Trends Endocrinol Metab 15:311–315 (2004).
50.
Miller WL, Huang N, Agrawal V, Giacomini KM: Genetic variation in human P450 oxidoreductase. Mol Cell Endocrinol 300:180–184 (2009).
51.
Minutti CZ, Lacey JM, Magera MJ, Hahn SH, McCann M, et al: Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 89:3687–3693 (2004).
52.
New MI: Inborn errors of adrenal steroidogenesis. Mol Cell Endocrinol 211:75–83 (2003).
53.
Nordenstrom A, Marcus C, Axelson M, Wedell A, Ritzen EM: Failure of cortisone acetate treatment in congenital adrenal hyperplasia because of defective hydroxysteroid dehydrogenase reductase activity. 84:1210–1213 (1999).
54.
Olney RC, Mougey EB, Wang J, Shulman DI, Sylvester J: Using real-time, quantitative PCR for rapid genotyping of the steroid 21-hydroxylase gene in a north Florida population. J Clin Endocrinol Metab 87:735–741 (2002).
55.
Pang S, Clark A: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: newborn screening and its relationship to the diagnosis and treatment of the disorder. Screening 2:105–139 (1993).
56.
Parajes S, Quinteiro, Dominguez F, Loidi L: High frequency of copy number variations and sequence variants at CYP21A2 locus: implication for the genetic diagnosis of 21-hydroxylase deficiency. PloS One 3:e2138(2008).
57.
Penny R, Vecsei P: Congenital adrenal hyperplasia due to combined 21- and 11-hydroxylase deficiency. J Endocrinol Invest 12:723–728 (1989).
58.
Riepe FG, Sippel WG: Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Rev Endocr Metab Disord 8:349–363 (2007).
59.
Riepe FG, Hiort O, Grötzinger J, Sippell WG, Krone N, et al: Functional and structural consequences of a novel point mutation in the CYP21A2 gene causing congenital adrenal hyperplasia: potential relevance of helix C for P450 oxidoreductase-21-hydroxylase interaction. J Clin Endocrinol Metab 93:2891–2895 (2008).
60.
Robins T, Carlsson J, Sunnerhagen M, Wedell A, Persson B: Molecular model of human CYP21 based on mammalian CYP2C5: structural features correlate with clinical severity of mutations causing congenital adrenal hyperplasia. Mol Endocrinol 20:2946–2964 (2006).
61.
Rocha RO, Billerbeck AE, Pinto EM, Melo KF, Lin CJ, et al: The degree of external genitalia virilization in girls with 21-hydroxylase deficiency appears to be influenced by the CAG repeats in the androgen receptor gene. Clin Endocrinol 68:226–232 (2008).
62.
Scott RR, Gomes LG, Huang N, Van Vliet G, Miller WL: Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency. J Clin Endocrinol Metab 92:2318–2322 (2007).
63.
Sikora A, Zimmermann BG, Rusterholz C, Birri D, Kolla V, et al: Detection of increased amounts of cell-free fetal DNA with short PCR amplicons. Clin Chem 56:136–138 (2010).
64.
Silveira EL, Elnecave RH, dos Santos EP, Moura V, Pinto EM, et al: Molecular analysis of CYP21A2 can optimize the follow-up of positive results in newborn screening for congenital adrenal hyperplasia. Clin Genet 76:503–510 (2009).
65.
Sinnott PJ, Costigan C, Dyer PA, Harris R, Strachan T: Extended MHC haplotypes and CYP21/C4 gene organisation in Irish 21-hydroxylase deficiency families. Hum Genet 87:361–366 (1991).
66.
Speiser PW, Dupont B, Rubinstain P et al: High frequency of non classical steroid 21-hydroxylase deficiency. Am J Hum Genet 37:650–667 (1985).
67.
Speiser PW, Agdere L, Ueshiba H, White PC, New MI: Aldosterone synthesis in salt-wasting congenital adrenal hyperplasia with complete absence of adrenal 21-hydroxylase. N Engl J Med 324:145–149 (1991).
68.
Speiser PW, Dupont J, Zhu D, Serrat J, Buegeleisen M, et al: Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 90:584–595 (1992).
69.
Stanghellini I, Bertorelli R, Capone L, Mazza V, Neri C, et al: Quantitation of fetal DNA in maternal serum during the first trimester of pregnancy by the use of a DAZ repetitive probe. Mol Hum Reprod 12:587–591 (2006).
70.
Tajima T, Okada T, Ma XM, Ramsey W, Bornstein S, et al: Restoration of adrenal steroidogenesis by adenovirus-mediated transfer of human cytochromeP450 21-hydroxylase into the adrenal gland of 21-hydroxylase-deficient mice. Gene Ther 6:1898–1903 (1999).
71.
Tang DL, Li Y, Zhou X, Li X, Zheng F: Multiplex fluorescent PCR for noninvasive prenatal detection of fetal-derived paternally inherited diseases using circulatory fetal DNA in maternal plasma. Eur J Obstet Gynecol Reprod Biol 144:35–39 (2009).
72.
Tonetto-Fernandes V, Lemos-Marini SH, Kuperman H, Ribeiro-Neto LM, Verreschi IT, et al: Serum 21-deoxycortisol, 17-hydroxyprogesterone, and 11-deoxycortisol in classic congenital adrenal hyperplasia: clinical and hormonal correlations and identification of patients with 11beta-hydroxylase deficiency among a large group with alleged 21-hydroxylase deficiency. J Clin Endocrinol Metab 91:2179–2184 (2006).
73.
Wedell A, Thilén A, Ritzén EM, Stengler B, Luthman H: Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation. J Clin Endocrinol Metab 78:1145–1152 (1994a).
74.
Wedell A, Stengler B, Luthman H: Characterization of mutations on the rare duplicated C4/CYP21 haplotype in steroid 21-hydroxylase deficiency. Hum Genet 94:50–54 (1994b).
75.
Welzel M, Schwarz P, Hedderich J, Dorr HG, Binder G, et al: No correlation between androgen receptor CAG and GGN repeat length and the degree of genital virilization in females with 21-hydroxylase deficiency. J Clin Endocrinol Metab, Epub ahead of print, doi:10.1210/jc.2009-133822 (2010).
76.
White PC: Neonatal screening for congenital adrenal hyperplasia. Nat Rev Endocrinol 5:490–498 (2009).
77.
White PC, Speiser PW: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev21:245–291 (2000).
78.
Wilkins L, Lewis RA, Klein R, Rosemberg E: The suppression of androgen secretion by cortisone in a case of congenital adrenal hyperplasia. Bull Johns Hopkins Hosp 86:249–252 (1950).
79.
Yamazaki H, Shimada T: Progesterone and testosterone hydroxylation by cytochromes P4502C19, 2C9 and 3A4. Arch Biochem Biophys 346:161–169 (1997).
80.
Yang Z, Mendoza AR, Welch TR, Zipf WB, Yu CY: Modular variations of the human major histocompatibility complex class III genes for serine/threonine kinase RP, complement component C4, steroid 21-hydroxylase CYP21, and tenascin TNX (the RCCX module). A mechanism for gene deletions and disease associations. J Biol Chem 274:12147–12156 (1999).
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.